arctic semaglutide Microdose Novo kidney trial finds Ozempic

doi: 10.1016/j.jad.2022.07.015 81 KamalM

Characterization of binding of uptake of 3,3,5-triiodo-L-thyronine in cultured mouse fibroblasts

Post-6-week acceleration typically continues as doses reach therapeutic levels

In recent years, several observational studies have suggested that GLP-1 drugs may be associated with lower risks for certain cancers or improved outcomes among cancer survivors

At baseline, cardiovascular disease and risk factors were managed with lipid-lowering therapy (90%), platelet aggregation inhibitors (86%), angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (74%), and beta blockers (70%)

Changes in kidney metabolism and blood vessel function are important elements in the progression of the disease (29)